2-Amino-5-phosphonovalerate (2 Amino 5 phosphonovalerate)

Subscribe to Selected New Research on 2-Amino-5-phosphonovalerate

84 relevant articles (4 outcomes, 5 trials/studies) found for this Bio-Agent

Description: The D-enantiomer is a potent and specific antagonist of NMDA glutamate receptors (RECEPTORS, N-METHYL-D-ASPARTATE). The L form is inactive at NMDA receptors but may affect the AP4 (2-amino-4-phosphonobutyrate; APB) excitatory amino acid receptors.

Also Known As:

2 Amino 5 phosphonovalerate; 2 Amino 5 phosphonopentanoate; 2-APV; 2-Amino-5-phosphonopentanoate; 5-Phosphononorvaline; d-APV; dl-APV; 2 Amino 5 phosphonopentanoic Acid; 2 Amino 5 phosphonovaleric Acid; 5 Phosphononorvaline; 2-Amino-5-phosphonopentanoic Acid; 2-Amino-5-phosphonovaleric Acid; Norvaline, 5-phosphono-

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins

Amino Acids: 8532

Branched-Chain Amino Acids: 524

Valine: 951

2-Amino-5-phosphonovalerate: 84

2-amino-4-methyl-5-phosphono-3-pentenoic acid: 52

2-amino-7-phosphonoheptanoic acid: 34

CGP 39551: 21

CGP 39653: 2

CGP 43487: 2

2-amino-5-phosphono-3-pentenoic acid

Phosphoamino Acids: 3

2-Amino-5-phosphonovalerate: 84

2-amino-4-methyl-5-phosphono-3-pentenoic acid: 52

2-amino-7-phosphonoheptanoic acid: 34

CGP 39551: 21

CGP 39653: 2

CGP 43487: 2

2-amino-5-phosphono-3-pentenoic acid

Experts

1.	Lu, Ying: 1 article (03/2003)
2.	Vera-Portocarrero, Louis P: 1 article (03/2003)
3.	Westlund, Karin N: 1 article (03/2003)

Related Diseases

1.	Seizures (Seizure) 10/01/2006 - "Changes were more profound and qualitatively different in TTX- compared with D-APV-treated cultures, consistent with the dramatic effects of TTX treatment on seizure expression" 10/01/2006 - "Granule cell field potential recordings in physiological buffer revealed spontaneous electrographic seizures in 83% of TTX-, 9% of D-APV-, but 0% of vehicle-treated cultures" 04/22/1988 - "In contrast, D(-)APV had no effect on KA-induced wet dog shakes or on behavioral seizures" 11/01/1998 - "The anticonvulsant potency of (+/-)-2-Amino-7-phosphonoheptanoic acid and (+/-)-2-amino-5-phosphonovaleric acid against metaphit-induced audiogenic seizures in rats." 08/28/1992 - "D-APV, an N-methyl-D-aspartate (NMDA) antagonist, stereoselectively blocked the development of seizures" Order ALL the reference details at left...
2.	Pancreatitis 03/01/2003 - "Intrathecal coadministration of D-APV and morphine is maximally effective in a rat experimental pancreatitis model." 03/01/2003 - "CONCLUSIONS: Spinal administration of combined doses of NMDA receptor antagonist, D-APV, and MS reversed three behavioral responses to induction of an acute pancreatitis model" 03/01/2003 - "The current study examined spinal coadministration of low doses of NMDA receptor antagonist, D-(-)-2-Amino-5-phosphonovalerate (D-APV), and mu-opioid receptor agonist, morphine sulfate (MS), in reducing visceral nociception using an acute bradykinin induced pancreatitis model in rats" Order ALL the reference details at left...
3.	Anoxia (Hypoxia) 05/28/1993 - "Bath application of D-APV (30 microM) prevented the significant reduction in the AD onset latency to the second hypoxia, but had no significant effect on the AD amplitude and duration" 05/28/1993 - "The hypoxia-induced decrease in [Ca2+]o was not altered after addition of D-APV to the bathing medium" 01/01/2003 - "The selected NMDA receptor antagonists 2-amino-5-phosphonopentanoate (AP5) added in the perfusion medium after the anoxia, did not eliminate the neuroprotective effect of CRF." 11/01/1991 - "2-APV and DGAMS are superior to MK-801 in preventing hypoxia-induced injury to developing neurons in vitro." 11/01/1987 - "Cultures exposed to hypoxia for 8 hr showed by the following day widespread neuronal injury, which was substantially attenuated by addition of the specific N-methyl-D-aspartate (NMDA) receptor antagonist 2-amino-5-phosphonovalerate (APV)" Order ALL the reference details at left...
4.	Ischemia 09/19/1994 - "The PIP was not affected by 2-amino-5-phosphonovalerate (APV) administered via microdialysis at 7 h post-ischemia" 08/04/1986 - "D-APV reduced the extracellular accumulation of all measured purine catabolites during ischemia/reflow and improved to some extent the recovery of the striatal electroencephalographic activity in the majority of the animals" 04/01/1991 - "Blockade of N-methyl-D-aspartate-sensitive excitatory amino acid receptors with 2-amino-5-phosphonovalerate reduces ischemia-evoked calcium redistribution in rabbit hippocampus." 04/01/1991 - "To evaluate the participation of excitatory amino acid receptors sensitive to N-methyl-D-aspartate (NMDA) in ischemia-evoked redistribution of Ca2+ ions from the extra- to the intracellular compartment of the hippocampus, 2-amino-5-phosphonovalerate (APV), a specific antagonist of NMDA receptors, was administered to the rabbit hippocampus through a dialysis probe before, during, and after complete reversible 15-min cerebral ischemia" 02/01/1994 - "The effects of the following drugs: nimodipine (1 mg/kg b.w., i.p.), 2-amino-5-phosphonovaleric acid (4 mg/kg b.w., i.p.) and propentofylline (25 mg/kg b.w., i.p.), administered (alone or in combination) at the end of 15 min bilateral ischemia in gerbils were evaluated on mitochondrial superoxide dismutase (SOD), glutathione reductase (GR), glucose-6 phosphate dehydrogenase (G6PD), monoamine oxidase (MAO) activities, and thiobarbituric acid reactive material (TBARM), and brain water content at 1 hour of reperfusion" Order ALL the reference details at left...
5.	Hyperalgesia 05/01/1997 - "Treatment with D-APV, but not saline, in the contralateral (but not ipsilateral) thalamus significantly reduced both the acute thermal and mechanical hyperalgesia in the injected paw; these same rats demonstrated significantly less thermal and mechanical hyperalgesia in the sub-acute phase than rats that had received saline or D-APV in the ipsilateral thalamus" 04/01/2003 - "There are four principle findings: 1) PDR as well as CCD and CCI induced thermal hyperalgesia; 2) PDR produced significantly less severe and shorter duration hyperalgesia than CCD and CCI; 3) intrathecal administration of NMDA receptor antagonists d-2-amino-5-phosphonovaleric acid (APV) and dizocilpine maleate (MK-801) inhibited thermal hyperalgesia in PDR, CCD, and CCI rats" 10/01/1996 - "The spinally-induced PGE2 hyperalgesia was antagonized by intrathecal injections (9 micrograms) of AP5 (2-amino-5-phosphonopentanoate/2-amino-5) a selective NMDA receptor antagonist" 11/01/2002 - "co-administration of the NMDA receptor antagonist D(-)-2-amino-5-phosphonovaleric acid (D-APV) with BDNF dose-dependently inhibits BDNF-induced hyperalgesia, suggesting that BDNF induces acute hyperalgesic responses and affects central sensitization in a process dependent on NMDA receptor activation." 05/01/1999 - "Furthermore, thermal hyperalgesia was significantly inhibited by the N-methyl-D-aspartate (NMDA) receptor antagonists, 2-amino-5-phosphonopentanoate (APV), dizocilpine and ifenprodil" Order ALL the reference details at left...

Related Drugs and Biologics

1.	N-Methylaspartate (NMDA)
2.	Morphine (MS Contin)
3.	2-amino-7-phosphonoheptanoic acid
4.	Aminophylline (Carine)
5.	purine
6.	Dizocilpine Maleate (Dizocilpine)
7.	NG-Nitroarginine Methyl Ester (L-NAME)
8.	Nitric Oxide Synthase (NO Synthase)
9.	mu Opioid Receptors (mu Opioid Receptor)
10.	Freund's Adjuvant

Related Therapies and Procedures

1.	Electrodes (Electrode)
2.	Electroacupuncture

Best Treatments:
Research Summary Report
on Seizures

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 2076 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>